Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 32

Results For "ITU"

1919 News Found

Gilead’s Trodelvy falls short on progression-free survival in key breast cancer trial
Clinical Trials | November 10, 2025

Gilead’s Trodelvy falls short on progression-free survival in key breast cancer trial

While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage


Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
News | November 10, 2025

Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr

Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives


Novo Nordisk India partners with Emcure to commercialise Poviztra in India
News | November 10, 2025

Novo Nordisk India partners with Emcure to commercialise Poviztra in India

Poviztra is a second brand of Wegovy


Valneva’s next-gen Zika vaccine shows strong safety and immune response in phase I trial
Clinical Trials | November 07, 2025

Valneva’s next-gen Zika vaccine shows strong safety and immune response in phase I trial

VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus


Zydus wellness reports 31% growth in net sales in Q2 FY26
News | November 06, 2025

Zydus wellness reports 31% growth in net sales in Q2 FY26

During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries


J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial
News | November 06, 2025

J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial

The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year


FDA approves UCB’s Kygevvi for rare genetic mitochondrial disease TK2 deficiency
Drug Approval | November 06, 2025

FDA approves UCB’s Kygevvi for rare genetic mitochondrial disease TK2 deficiency

Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA


Teva reports 11th consecutive quarter of growth
News | November 06, 2025

Teva reports 11th consecutive quarter of growth

Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.


Effective corrosion management demands a holistic approach: Experts
News | November 04, 2025

Effective corrosion management demands a holistic approach: Experts

From material selection to cooling tower management, every small decision affects long-term equipment reliability